In addition, research results indicate that somatic activating mutations in KRAS may be associated with GSD and suggest that trametinib (a MEK inhibitor) may be an effective drug for the treatment of GSD [46]. The gene discussed is MAP2K7; the disease is disorder of glycogen metabolism.